Altimmune, Inc. Stock News

GAITHERSBURG, Md., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that new data on the anti-inflammatory and anti-fibrotic

GAITHERSBURG, Md., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will parti

Altimmune's stock has disappointed shareholders over the past year, with disappointing trial results triggering a significant drop in equity in March of this year. The Company is developing treatments

Penny stocks, typically defined as stocks trading under $5 per share, offer traders massive upside profit potential but also higher risk due to greater volatility. When penny stocks become heavily sho

Altimmune (ALT) completes the dosing of all patients in the mid-stage obesity study of pemvidutide. The company remains on track to announce top-line results in fourth-quarter 2023.

GAITHERSBURG, Md., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will parti

GAITHERSBURG, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2023 financial re

Morgan Stanley on Friday lifted its forecast for annual sales of weight-loss drugs to $77 billion, as patient demand for the medicines has outstripped supply and been fueled by a social-media frenzy.

Drug developers are chasing an obesity drug gold rush that may be worth up to $100 billion by rolling out treatments that can help lose as much as 24% of weight in less than a year.

GAITHERSBURG, Md., June 16, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmun

GAITHERSBURG, Md., May 31, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will partic

GAITHERSBURG, Md., May 08, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will partic

GAITHERSBURG, Md., May 04, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2023 financial resu

The biotech sector is up 4.76% so far in 2023. This continues the nice run that biotech stocks had in 2022.

10 Penny stocks under $5 to watch right now The post Top Penny Stocks To Buy Now? 10 To Watch Under $5 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.